Apnimed to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Apnimed to Participate in Upcoming Leerink Partners Global Biopharma Conference
Apnimed to Participate in the Upcoming Evercore ISI 2024 Emerging Biotech Conference
Apnimed, which has a novel sleep apnea drug in Phase III, is considering a potential IPO in the second half of this year even as biotech entries to Wall Street have started to slow.
Apnimed Announces New Leadership Appointments as It Builds Commercial & HR Capabilities in Support of AD109, a Potential Nighttime Oral Treatment for OSA
Apnimed named a new chief commercial officer on Monday, tapping Graham Goodrich, a veteran biopharma marketing executive, to start building out a team to commercialize its oral sleep apnea candidate now in Phase III studies.
-- SynAIRgy Compares AD109 to Placebo Over 6 Months in People with OSA who Are Intolerant of or Refuse Positive Airway Pressure (PAP) Therapy, the Current Standard of Care -- Part of a two-study...
CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Apnimed Announces Launch of Joint Venture with Shionogi
CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea...